Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AWH NASDAQ:DWTX NASDAQ:RNAZ NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAWHAspira Women's Health$0.08-12.5%$0.08$0.08▼$1.56$2.44M2.011.62 million shs4.31 million shsDWTXDogwood Therapeutics$4.83-1.2%$4.86$1.62▼$29.28$9.35M1.820,373 shs11,787 shsRNAZTransCode Therapeutics$10.39-2.4%$8.92$6.15▼$739.20$8.66M1.46251,374 shs17,410 shsSNGXSoligenix$2.90-11.9%$1.71$1.09▼$5.40$9.47M1.9522.14 million shs1.01 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAWHAspira Women's Health0.00%0.00%0.00%0.00%-92.93%DWTXDogwood Therapeutics0.00%-0.41%-3.21%+5.92%+482,999,900.00%RNAZTransCode Therapeutics0.00%-9.65%+15.44%+11.84%-99.87%SNGXSoligenix0.00%+5.84%+128.35%+46.84%-14.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAWHAspira Women's HealthN/AN/AN/AN/AN/AN/AN/AN/ADWTXDogwood Therapeutics1.2717 of 5 stars3.50.00.00.00.60.00.6RNAZTransCode Therapeutics1.9331 of 5 stars3.54.00.00.00.60.00.6SNGXSoligenix2.2677 of 5 stars3.52.00.00.03.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAWHAspira Women's Health 3.00Buy$5.506,607.32% UpsideDWTXDogwood Therapeutics 3.00Buy$10.00107.04% UpsideRNAZTransCode Therapeutics 3.00Buy$280.002,594.90% UpsideSNGXSoligenix 3.00Buy$6.00106.90% UpsideCurrent Analyst Ratings BreakdownLatest AWH, SNGX, RNAZ, and DWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025SNGXSoligenixAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.00(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAWHAspira Women's Health$9.18M0.27N/AN/A($0.23) per share-0.36DWTXDogwood TherapeuticsN/AN/AN/AN/A($7.56) per shareN/ARNAZTransCode TherapeuticsN/AN/AN/AN/A($54.96) per shareN/ASNGXSoligenix$120K78.78N/AN/A$1.64 per share1.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAWHAspira Women's Health-$16.69M-$0.98N/A∞N/A-165.07%N/A-267.23%8/11/2025 (Estimated)DWTXDogwood Therapeutics-$12.35M-$18.04N/AN/AN/AN/AN/A-34.74%8/13/2025 (Estimated)RNAZTransCode Therapeutics-$16.75MN/A0.00N/AN/AN/A-578.88%-222.61%8/13/2025 (Estimated)SNGXSoligenix-$8.27M-$4.29N/AN/AN/AN/A-223.89%-103.50%N/ALatest AWH, SNGX, RNAZ, and DWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025DWTXDogwood Therapeutics-$1.26N/AN/AN/AN/AN/A5/21/2025Q4 2024RNAZTransCode Therapeutics-$2.00-$0.60+$1.40-$2.51$0.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAWHAspira Women's Health$1.041,268.29%N/AN/A N/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAWHAspira Women's HealthN/A0.750.70DWTXDogwood TherapeuticsN/A7.437.43RNAZTransCode TherapeuticsN/A5.205.20SNGXSoligenixN/A1.851.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAWHAspira Women's Health12.19%DWTXDogwood Therapeutics9.05%RNAZTransCode TherapeuticsN/ASNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipAWHAspira Women's Health4.30%DWTXDogwood Therapeutics3.90%RNAZTransCode Therapeutics0.01%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAWHAspira Women's Health11029.76 million16.92 millionNo DataDWTXDogwood Therapeutics51.91 million1.84 millionN/ARNAZTransCode Therapeutics9830,000834,000Not OptionableSNGXSoligenix203.26 million3.16 millionNot OptionableAWH, SNGX, RNAZ, and DWTX HeadlinesRecent News About These CompaniesSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL TherapyAugust 8 at 11:41 PM | finance.yahoo.comNetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin CancerAugust 8 at 8:30 AM | globenewswire.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...August 7 at 9:22 AM | gurufocus.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...August 7 at 9:22 AM | gurufocus.comSoligenix (SNGX) Expected to Announce Quarterly Earnings on FridayAugust 6, 2025 | americanbankingnews.comSoligenix Completes Phase 2a Study for SGX945August 6, 2025 | theglobeandmail.comSoligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL SpaceAugust 5, 2025 | finance.yahoo.comSoligenix Inc. (NASDAQ:SNGX) Short Interest Up 248.7% in JulyAugust 5, 2025 | americanbankingnews.comLate-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic AreasAugust 4, 2025 | newswire.caPromising Defense Stocks To Research - July 31stAugust 3, 2025 | americanbankingnews.comPenny Stocks To Keep An Eye On - July 31stAugust 3, 2025 | americanbankingnews.comPromising Small Cap Stocks To Consider - July 31stAugust 2, 2025 | americanbankingnews.comSoligenix has phase IIa success in rare disease Behçet'sAugust 1, 2025 | bioworld.comBWhy Is Soligenix Stock (SNGX) Up 50% Today?August 1, 2025 | msn.comSoligenix (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet’s DiseaseJuly 31, 2025 | theglobeandmail.comSNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet’s Disease…July 31, 2025 | finance.yahoo.comBiological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's DiseaseJuly 31, 2025 | prnewswire.comTargeting the Unmet: Soligenix (NASDAQ: SNGX) Building Portfolio for Rare ConditionsJuly 28, 2025 | theglobeandmail.comSNGX: Multiple Catalysts Upcoming in 2H25…July 11, 2025 | finance.yahoo.comSoligenix Corporate Update Letter - Key Highlights and Upcoming MilestonesJuly 8, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAWH, SNGX, RNAZ, and DWTX Company DescriptionsAspira Women's Health NASDAQ:AWHAspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.Dogwood Therapeutics NASDAQ:DWTX$4.83 -0.06 (-1.23%) Closing price 08/8/2025 03:58 PM EasternExtended Trading$4.92 +0.09 (+1.86%) As of 08/8/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.TransCode Therapeutics NASDAQ:RNAZ$10.39 -0.26 (-2.44%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$10.04 -0.35 (-3.32%) As of 08/8/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.Soligenix NASDAQ:SNGX$2.90 -0.39 (-11.85%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.95 +0.05 (+1.72%) As of 08/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
